FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283735462> ?p ?o ?g. }

• W4283735462 endingPage "e004646" @default.
• W4283735462 startingPage "e004646" @default.
• W4283735462 abstract "Both ganglioside GD2-targeted immunotherapy and antibody-drug conjugates (ADCs) have demonstrated clinical success as solid tumor therapies in recent years, yet no research has been carried out to develop anti-GD2 ADCs against solid tumors. This is the first study to analyze cytotoxic activity of clinically relevant anti-GD2 ADCs in a wide panel of cell lines with varying GD2 expression and their effects in mouse models of GD2-positive solid cancer.Anti-GD2 ADCs were generated based on the GD2-specific antibody ch14.18 approved for the treatment of neuroblastoma and commonly used drugs monomethyl auristatin E (MMAE) or F (MMAF), conjugated via a cleavable linker by thiol-maleimide chemistry. The antibody was produced in a mammalian expression system, and its specific binding to GD2 was analyzed. Antigen-binding properties and biodistribution of the ADCs in mice were studied in comparison with the parent antibody. Cytotoxic effects of the ADCs were evaluated in a wide panel of GD2-positive and GD2-negative tumor cell lines of neuroblastoma, glioma, sarcoma, melanoma, and breast cancer. Their antitumor effects were studied in the B78-D14 melanoma and EL-4 lymphoma syngeneic mouse models.The ch14.18-MMAE and ch14.18-MMAF ADCs retained antigen-binding properties of the parent antibody. Direct dependence of the cytotoxic effect on the level of GD2 expression was observed in cell lines of different origin for both ADCs, with IC50 below 1 nM for the cells with high GD2 expression and no cytotoxic effect for GD2-negative cells. Within the analyzed cell lines, ch14.18-MMAF was more effective in the cells overexpressing GD2, while ch14.18-MMAE had more prominent activity in the cells expressing low GD2 levels. The ADCs had a similar biodistribution profile in the B78-D14 melanoma model compared with the parent antibody, reaching 7.7% ID/g in the tumor at 48 hours postinjection. The average tumor size in groups treated with ch14.18-MMAE or ch14.18-MMAF was 2.6 times and 3.8 times smaller, respectively, compared with the control group. Antitumor effects of the anti-GD2 ADCs were also confirmed in the EL-4 lymphoma model.These findings validate the potential of ADCs targeting ganglioside GD2 in treating multiple GD2-expressing solid tumors." @default.
• W4283735462 created "2022-07-01" @default.
• W4283735462 creator A5015318387 @default.
• W4283735462 creator A5015347520 @default.
• W4283735462 creator A5017821496 @default.
• W4283735462 creator A5019082390 @default.
• W4283735462 creator A5032201823 @default.
• W4283735462 creator A5032775715 @default.
• W4283735462 creator A5035909327 @default.
• W4283735462 creator A5049263019 @default.
• W4283735462 creator A5058335791 @default.
• W4283735462 creator A5074978501 @default.
• W4283735462 creator A5076678402 @default.
• W4283735462 date "2022-06-01" @default.
• W4283735462 modified "2023-10-18" @default.
• W4283735462 title "Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors" @default.
• W4283735462 cites W128154692 @default.
• W4283735462 cites W1481048913 @default.
• W4283735462 cites W1495717648 @default.
• W4283735462 cites W1573748938 @default.
• W4283735462 cites W1892975056 @default.
• W4283735462 cites W1901785997 @default.
• W4283735462 cites W1988001137 @default.
• W4283735462 cites W2019629676 @default.
• W4283735462 cites W2040796340 @default.
• W4283735462 cites W2046185660 @default.
• W4283735462 cites W2102913940 @default.
• W4283735462 cites W2110134768 @default.
• W4283735462 cites W2122559638 @default.
• W4283735462 cites W2149820534 @default.
• W4283735462 cites W2171368669 @default.
• W4283735462 cites W2288867196 @default.
• W4283735462 cites W2413419627 @default.
• W4283735462 cites W2422191365 @default.
• W4283735462 cites W2526956956 @default.
• W4283735462 cites W2567681842 @default.
• W4283735462 cites W2605265954 @default.
• W4283735462 cites W2766319190 @default.
• W4283735462 cites W2830206124 @default.
• W4283735462 cites W2915626874 @default.
• W4283735462 cites W2940558767 @default.
• W4283735462 cites W2950827632 @default.
• W4283735462 cites W2981320757 @default.
• W4283735462 cites W3012446957 @default.
• W4283735462 cites W3023552131 @default.
• W4283735462 cites W3028603350 @default.
• W4283735462 cites W3041156479 @default.
• W4283735462 cites W3046157728 @default.
• W4283735462 cites W3088832985 @default.
• W4283735462 cites W3123681476 @default.
• W4283735462 cites W3129393016 @default.
• W4283735462 cites W3158967353 @default.
• W4283735462 cites W3162216940 @default.
• W4283735462 cites W3164659665 @default.
• W4283735462 cites W3167756601 @default.
• W4283735462 cites W3173687939 @default.
• W4283735462 cites W3185273357 @default.
• W4283735462 cites W3187978533 @default.
• W4283735462 cites W3194861850 @default.
• W4283735462 cites W3198722228 @default.
• W4283735462 cites W3199389719 @default.
• W4283735462 cites W3204138292 @default.
• W4283735462 cites W4210246844 @default.
• W4283735462 doi "https://doi.org/10.1136/jitc-2022-004646" @default.
• W4283735462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35764367" @default.
• W4283735462 hasPublicationYear "2022" @default.
• W4283735462 type Work @default.
• W4283735462 citedByCount "9" @default.
• W4283735462 countsByYear W42837354622023 @default.
• W4283735462 crossrefType "journal-article" @default.
• W4283735462 hasAuthorship W4283735462A5015318387 @default.
• W4283735462 hasAuthorship W4283735462A5015347520 @default.
• W4283735462 hasAuthorship W4283735462A5017821496 @default.
• W4283735462 hasAuthorship W4283735462A5019082390 @default.
• W4283735462 hasAuthorship W4283735462A5032201823 @default.
• W4283735462 hasAuthorship W4283735462A5032775715 @default.
• W4283735462 hasAuthorship W4283735462A5035909327 @default.
• W4283735462 hasAuthorship W4283735462A5049263019 @default.
• W4283735462 hasAuthorship W4283735462A5058335791 @default.
• W4283735462 hasAuthorship W4283735462A5074978501 @default.
• W4283735462 hasAuthorship W4283735462A5076678402 @default.
• W4283735462 hasBestOaLocation W42837354621 @default.
• W4283735462 hasConcept C121608353 @default.
• W4283735462 hasConcept C126322002 @default.
• W4283735462 hasConcept C147483822 @default.
• W4283735462 hasConcept C154317977 @default.
• W4283735462 hasConcept C159654299 @default.
• W4283735462 hasConcept C185592680 @default.
• W4283735462 hasConcept C202751555 @default.
• W4283735462 hasConcept C203014093 @default.
• W4283735462 hasConcept C2776715637 @default.
• W4283735462 hasConcept C2777325958 @default.
• W4283735462 hasConcept C2777658100 @default.
• W4283735462 hasConcept C2777701055 @default.
• W4283735462 hasConcept C2778245361 @default.
• W4283735462 hasConcept C502942594 @default.
• W4283735462 hasConcept C542903549 @default.
• W4283735462 hasConcept C54355233 @default.

• next